Abbott To Buy Russia's Petrovax In Deal Worth As Much As $500 Million
This article was originally published in PharmAsia News
Executive Summary
Abbott Laboratories plans to acquire Russia's Petrovax Pharm for as much as $500 million for access to the nation's 12th largest drug maker, a specialist in vaccines.